

Ref: EPL/CS/SE/0088/2026

Date: October 12, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on October 12, 2026 - Scheme of Amalgamation of certain wholly owned subsidiaries with Emcure Pharmaceuticals Limited - Holding Company.

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “**SEBI Listing Regulations**”), we wish to inform you that the Board of Directors at its meeting held on Monday, October 12, 2026 has *inter alia*, approved the draft Composite Scheme of Amalgamation amongst Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited (collectively referred to as the “**Transferor Companies**”) both being wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited (hereinafter referred to as the “**Company**” or “**Transferee Company**”) and their respective shareholders and creditors pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“**Scheme**”).

The Scheme is subject to necessary statutory and regulatory approvals under applicable laws, including the approval of the Hon'ble National Company Law Tribunal, Mumbai Bench.

The disclosure as required pursuant to Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular HO/49/ 14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed herewith and marked as **Annexure A**.

The meeting of the Board of Directors of the Company commenced at 09:45 a.m. (IST) and concluded at 10: 10 a.m. (IST).

You are requested to take the above information on your records.

Thanking you,
For **Emcure Pharmaceuticals Limited**

Digitally signed by
AMRUTA AMIT
YANGALWAR
Date: 2026.10.12 10:18:29
+05'30'

Amruta Yangalwar
Company Secretary & Compliance Officer
ICSI Membership No.: A25687

Encl: As above

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Annexure - A

Disclosure Required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Sr. No.	Particulars	Details												
1	Name of the entity(ies) forming part of the amalgamation/merger, details in brief such as size, turnover, etc.	Transferor Companies: Zuventus Healthcare Limited Emcutix Biopharmaceuticals Limited Transferee Company: Emcure Pharmaceuticals Limited (INR in crores) <table> <tr> <th>Name of Company</th><th>Networth as on March 31, 2026</th><th>Turnover for FY 2025-26</th></tr> <tr> <td>Zuventus Healthcare Limited</td><td>871.46</td><td>1,040.58</td></tr> <tr> <td>Emcutix Biopharmaceuticals Limited</td><td>(13.07)</td><td>29.37</td></tr> <tr> <td>Emcure Pharmaceuticals Limited</td><td>3,710.60</td><td>5,243.19</td></tr> </table>	Name of Company	Networth as on March 31, 2026	Turnover for FY 2025-26	Zuventus Healthcare Limited	871.46	1,040.58	Emcutix Biopharmaceuticals Limited	(13.07)	29.37	Emcure Pharmaceuticals Limited	3,710.60	5,243.19
Name of Company	Networth as on March 31, 2026	Turnover for FY 2025-26												
Zuventus Healthcare Limited	871.46	1,040.58												
Emcutix Biopharmaceuticals Limited	(13.07)	29.37												
Emcure Pharmaceuticals Limited	3,710.60	5,243.19												
2	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	The Scheme involves the amalgamation of wholly owned subsidiary companies with the holding company. Therefore, it is exempted as per Regulation 23(5)(b) of the SEBI Listing Regulations. Furthermore, in accordance with the General Circular No. 30/2014 dated July 17, 2014, issued by the Ministry of Corporate Affairs, transactions resulting from compromises, arrangements, and amalgamations under the Companies Act 2013, are not subject to the requirements of Section 188 of Companies Act, 2013.												
3	Area of business of the entity(ies)	Pharmaceutical												
4	Rationale for amalgamation/merger	To achieve entity rationalization and operational efficiency within the group.												
5	In case of cash consideration - amount or otherwise share exchange ratio consideration	No consideration shall be payable. The entire share capital of Transferor Companies is held by the Company and no shares shall be issued pursuant to the Scheme.												
6	Brief details of change in shareholding pattern (if any) of the listed entity	There will be no change in the shareholding pattern of the Company pursuant to the aforesaid Scheme, as no shares would be issued by the Company in consideration for the amalgamation.												

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251